ArticleInternational journal of general medicine2026
Prognostic Significance of the CALLY Index in Heart Failure.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) is a global health problem with high mortality rates. Systemic inflammation and neurohumoral dysfunction play an important role in its pathophysiology. Unlike other subtypes, HF with preserved ejection fraction (HFpEF) represents a highly heterogeneous group of patients. Therefore, the phenotyping must be conducted with great care. Objective: In our study, we aimed to evaluate the relationship between the C-reactive protein-albumin-lymphocyte (CALLY)-index, a composite biomarker reflecting the nutritional, inflammation and immune status of the patient, and long-term mortality due to all causes in HF. Subjects and Methods: Our retrospective, single-centre study included patients diagnosed with HF and followed up at our clinic between 2018-2025. The CALLY-index was calculated using the patients' blood tests at the time of hospital admission. In this study, where the primary endpoint was all-cause mortality, patients were divided into two groups according to their survival status. Variables independently associated with mortality were identified using Cox-regression analysis. To assess the predictive power of the CALLY-index for mortality, a Receiver Operating Characteristic (ROC) analysis was performed and the area under the curve (AUC) was calculated. Results: Our study included 1541 patients, with a mean age of 69.39±12.82, 758 (49.2%) males, and a mean follow-up period of 5.51±2.37 years. The all-cause mortality rate in the sample was 9.6% (148 patients). Consequently, the CALLY-index showed an independent association with mortality in HF (P=0.002) and predicted mortality with a cut-off value of 0.43, a sensitivity of 66.2% and a specificity of 66.2% (AUC:0.715, P=0.001). When regression analyses were repeated by subgroup, an independent association between the CALLY-index and mortality was identified only in the HFpEF group, unlike in the others. In HFpEF, the CALLY-index predicted mortality with a sensitivity of 68.8% and a specificity of 68.7% at a cut-off value of 0.40 (AUC:0.744, P<0.001). Conclusion: This study has shown that the CALLY index may have prognostic value in HF, particularly in HFpEF. We believe that this could be important in identifying high-risk patients in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.